I would love to have you state your sources on the opportunistic infections data you shared. It seems you are just relating info from a non expert media reporter and it is fact that they have gotten most of the data wrong over the past 7-8 months. The fact is that opportunistic infection in the placebo control group was nearly equal to the
AFFIRM monotherapy trial group. Have you actually read the trials data or are you being misled by the media?
Most of the information that comes our way re: Tysabri these days is from articles that involve the financial world. Just read Biogen/Elan's press releases and you can see that they are geared toward the stock market. At the same time news reporters and financial analysts are always looking for information about Tysabri and these companies because of the impact it all has in the financial world. After all, when Tysabri got pulled off the market in February, the Biogen/Elan stock lost $ 17 billion overnight so it doesn't take a rocket scientist to understand why Biogen/Elan are being looked at so closely. A lot of people lost a lot of money....unless of course, you were the privileged few Biogen execs who made millions by selling their stock just before the withdrawal of Tysabri!!
Here is one source of the information that I read but there were others...
"This is the WSJ article (by Sylvia Pagan Westphal) now. Here's the gist:
Stephen Harr, a Morgan Stanley analyst, prepared a note based on adverse-event (AE) reports submitted to FDA, which the analyst obtained by a request under the Freedom of Information Act. In addition to the already-publicized fatalities from progressive multifocal leukoencephalopathy (PML), Harr noted the AE file documented 7 additional fatalities among Tysabri patients. One was attributed to pneumocystis pneumonia, another to herpes encephalitis, and four others to sepsis. The Tysabri AE file also documented "numerous" nonfatal infections.
Biogen, who markets the drug with Elan, has downplayed the significance of the data in the AE file. A Biogen spokesman said a Biogen/Elan analysis found no statistically significant differences in serious adverse events between Tysabri and a placebo in several clinical trials.
FDA has declined to comment."
Now the readers can choose to believe this reporter or not but why on earth would she go to the trouble of obtaining this info through the Freedom of Information route and then falsify what she discovered. Do you think for one minute that Biogen/Elan would publicly publish this info? Drug companies simply don't make available detrimental info about their products and for very good reason.....it doesn't exactly do sales much good!!!
Also, readers can choose to believe everything that Biogen/Elan provides us. I simply am not one of those readers and have been told by more than one person in medicine that Biogen is not reliable or to be trusted. And how they introduced Tysabri into the MS market certainly hasn't changed my opinion of them.